PL BioScience Reveals Fall 2025 Conferences Attendance PL BioScience announces participation in upcoming conferences this fall PL BioScience has revealed its participation in six upcoming Fall 2025 conferences. As part of its global strategy, the company will be represented in the following conferences in Asia and Europe:
PL BioScience Announces Major Site Expansion in September 2025 Key Milestone for PL BioScience as new headquarters are announced PL BioScience announced the next major step in its expansion – an upcoming move to a new 1,200 m² facility in Aachen, in September 2025. This key milestone
PL BioScience announces Strengthening of Management Team Appointment of Oliver Dick as new Chief Technology Officer PL BioScience announced the strengthening of its management team with the appointment of Oliver Dick, PhD. Oliver Dick joins the team as Chief Technology Officer, a strategic position as the company
First Artificial Human Platelet Lysate PL BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech
We are thrilled to unveil our latest innovation: ELAREM™ Ultimate-FD PLUS The gamma irradiated Human Platelet Lysate ELAREM™ Ultimate-FD PLUS is designed to meet the needs of cell manufacturing applications requiring proven viral reduction. As a xeno-free cell culture supplement, ELAREM™ Ultimate-FD PLUS supports the safe and
We are thrilled to announce a significant milestone for PL BioScience! In a recent press release, we reveal that we have successfully closed a €7.8 million Series A financing round. This Series A funding marks a pivotal moment in our company’s growth journey. This substantial infusion
